O. Glehen, F. Kwiatkowski, P. H. Sugarbaker, D. Elias, E. A. Levine, M. De Simone, R. Barone, Y. Yonemura, F. Cavaliere, F. Quenet, M. Gutman, A. A. Tentes, G. Lorimier, J. L. Bernard, J. M. Bereder, J. Porcheron, A. Gomez-Portilla, P. Shen, M. Deraco and P. Rat, “Cytoreductive Surgery Combined with Perioperative Intraperitoneal Chemotherapy for the Management of Peritoneal Carcinomatosis from Colorectal Cancer: A Multi-Institutional Study,” Journal of Clinical Oncology, Vol. 22, No. 16, 2004, pp. 3284-32

has been cited by the following article:

• TITLE: Peritoneal Colorectal Carcinomatosis Treated with Cytoreductive Surgery and Perioperative Intraperitoneal Chemotherapy

  AUTHORS: Antonios-Apostolos K. Tentes, Odysseas Korakianitis, Nikolaos Pallas, Christos Mavroudis, Panagiotis Sarlis, Anastasios Liberis, Athanasios Pagalos, Stephanos Popidis

  KEYWORDS: Colorectal Cancer; Peritoneal Carcinomatosis; Cytoreductive Surgery; Intraperitoneal Chemotherapy

  JOURNAL NAME: Surgical Science, Vol.3 No.2, February 24, 2012

  ABSTRACT: Background-Aims: Peritoneal colorectal carcinomatosis is a potentially curative disease. The purpose of the study is the retrospective analysis of survival of the patients with peritoneal colorectal carcinomatosis that underwent cytoreductive surgery and perioperative intraperitoneal chemotherapy and the identification of prognostic variables of the disease. Patients-Methods: Patients with primary or recurrent colorectal cancer and peritoneal carcinomatosis were included in the study. Clinical variables were correlated to survival, recurrence, hospital mortality, and morbidity. Results: From 2000-2010, 28 patients underwent 33 cytoreductive operations. The hospital mortality and morbidity rate was 9.1% and 45.5% respectively. The overall 5-year and median survival time was 29.2% and 19 months respectively. The extent of peritoneal carcinomatosis (p = 0.0003) and the completeness of cytoreduction (p = 0.0002) were related to survival. The completeness of cytoreduction (p = 0.003) was the single prognostic variable of survival. The recurrence rate was 42.4% and the use of systemic chemotherapy was identified as the single prognostic variable of recurrence (p = 0.047). Conclusions: Patients with limited extent of peritoneal colorectal carcinomatosis who undergo complete cytoreduction may be offered long-term survival.